Should antiretroviral therapy be started earlier?

Joel E. Gallant

Research output: Contribution to journalArticlepeer-review

Abstract

Current treatment guidelines recommend that antiretroviral therapy be deferred until the CD4 count has fallen into the 200 to 350 cells/mm 3 range. However, treatment has become simpler, less toxic, and more forgiving of missed doses. Longer-term follow-up data from clinical cohorts are now showing better outcomes when therapy is started at higher CD4 cell counts. Therapy initiated early has better virologic and immunologic responses, is better tolerated, and is cost-effective. Recent developments and clinical data support a return to earlier initiation of therapy.

Original languageEnglish (US)
Pages (from-to)53-59
Number of pages7
JournalCurrent HIV/AIDS Reports
Volume4
Issue number2
DOIs
StatePublished - May 2007

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Should antiretroviral therapy be started earlier?'. Together they form a unique fingerprint.

Cite this